Skip to main content

Eurofins Publishes Robust Method to Analyse SARS-CoV-2 in Wastewater Samples, Providing Early Warning of Potential COVID-19 Outbreak at a Given Site

A study undertaken by Eurofins scientists has resulted in a robust method to analyse SARS-CoV-2 in wastewater samples, allowing for early detection of virus presence at a given site, before the virus spreads too broadly or as a way to monitor the effectiveness of containment measures put in place. https://www.medrxiv.org/content/10.1101/2020.07.10.20150573v1

As part of the study, Eurofins team of scientists used wastewater samples which had been collected during the COVID-19 pandemic in Denmark. They were able to detect the virus in a sample taken three days before patient 0 was identified in the country.

The findings of this study are particularly relevant for municipalities, production facilities, hospitals, nursing homes etc. At those sites, wastewater testing, offered as part of the Eurofins COVID-19 Sentinel™ programme, can give an early indication of the presence of SARS-CoV-2, therefore allowing for relevant containment measures in order to avoid an outbreak of the disease. With a growing understanding of the very significant role pre-symptomatic and asymptomatic virus carriers play in the pandemic, early detection of virus presence on a site is a vital first step to identifying the potential carrier(s) and putting increased measures in place to contain the disease. As the method developed by Eurofins is semi-quantitative, it also offers a strong tool to monitor the development of an outbreak over time and the efficacy of the containment measures put in place when an outbreak is detected.

This waste water testing method comes as yet another powerful tool in the Eurofins COVID-19 Sentinel™ suite of tests to help with the identification and containment of the COVID-19 pandemic. In real life over the last few weeks without requiring human testing, the Eurofins COVID-19 Sentinel™ programme has demonstrated its capacity to detect the presence of the SARS-CoV-2 virus on a site, before the affected employee had symptoms and knew of his/her infection.

The full release can be found at: https://www.eurofins.com/media-centre/press-releases/2020-07-14/

About Eurofins, the global leader in Bioanalysis

With over 47,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts:

For further information, please visit www.eurofins.com:
Yvoine Rémy-McCort
ir@eurofins.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.